Impact of coenzyme Q10 as an adjuvant therapy to letrozole on spermiogram results and sex hormone levels in Iraqi men with infertility; randomized open label comparative study
F1000Research · 2024
DOI: 10.12688/f1000research.131985.3 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift F1000Research, 2024. Verfasst von Essa Bahauldeen Fadhil und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, College of Pharmacy, Mustansiriyah University, Baghdad, Baghdad Governorate, Iraq. Hauptthemen laut MEDLINE: Ubiquinone, Letrozole, Infertility, Male. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Worldwide, infertility affects about 15% of reproductive-age couples. In many cases, infertility can't be treated, however new treatment options with promising value have been involved in recent clinical trials. The aim of this clinical trial was to evaluate the impacts of adding coenzyme Q10 (CoQ10) to letrozole on the results of spermiogram and sex hormone tests in men diagnosed with idiopathic oligoasthenoteratozoospermia (iOAT) syndrome, which is a type of male defective spermatogenesis of unknown etiology.
Methods
This randomized, open-label, parallel two-arm interventional study included 67 adult male patients aged 18-60 years with a confirmed diagnosis of iOAT syndrome recruited from The High Institute for Infertility Diagnosis & Assisted Reproduction Technologies/Nahrain University. Patients were randomly separated into two groups, Group A included 29 patients treated with letrozole 2.5 mg tablet orally twice a week, Group B included 38 patients treated with a combination of letrozole 2.5 mg tablet orally twice a week plus CoQ10 400 mg per day. Both groups completed treatment for three months. Semen samples, serum follicle-stimulating hormone (FSH), estradiol (E2), and testosterone (T) were analyzed at day one, and at the end of month one, two and three.
Results
Both groups showed that sperm concentration, normal morphology, total sperm count and motility, serum testosterone and FSH levels, and T/E2 ratio were significantly increased, while estradiol levels significantly decreased after three months of treatment. Seminal fluid volume changed significantly in group A only. In comparing between the two groups, all measured parameters, apart from sperm motility and FSH level, demonstrated a significant difference after three months of treatment, while sperm volume reached significant value after only two months of therapy.
Conclusions
CoQ10 as adjuvant treatment to letrozole effectively improved most of the tested sperm parameters in Iraqi men with iOAT. Registration: ClinicalTrials.gov (NCT05847257, May 6, 2023).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, College of Pharmacy, Mustansiriyah University, Baghdad, Baghdad Governorate, Iraq.
- High Institute of Infertility Diagnosis and Assisted Reproductive Technologies, Al-Nahrain University, Baghdad, Baghdad Governorate, Iraq.
ORCID-Profile: Mohammed Mahmood Mohammed
Zitieren
APA
Fadhil, E. B., Mohammed, M. M., & Alkawaz, U. M. (2024). Impact of coenzyme Q10 as an adjuvant therapy to letrozole on spermiogram results and sex hormone levels in Iraqi men with infertility; randomized open label comparative study. F1000Research. https://doi.org/10.12688/f1000research.131985.3
Vancouver
Fadhil EB, Mohammed MM, Alkawaz UM. Impact of coenzyme Q10 as an adjuvant therapy to letrozole on spermiogram results and sex hormone levels in Iraqi men with infertility; randomized open label comparative study. F1000Research. 2024. doi:10.12688/f1000research.131985.3
BibTeX
@article{Fadhil2024,
author = {Fadhil, Essa Bahauldeen and Mohammed, Mohammed Mahmood and Alkawaz, Ula M},
title = {Impact of coenzyme Q10 as an adjuvant therapy to letrozole on spermiogram results and sex hormone levels in Iraqi men with infertility; randomized open label comparative study},
journal = {F1000Research},
year = {2024},
doi = {10.12688/f1000research.131985.3}
}
EUVIMED